Abstract: The present invention provides a novel human integral membrane (IMP-2) and polynucleotides which identify and encode IMP-2. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding IMP-2 and a method for producing IMP-2. The invention also provides for agonists, antibodies, or antagonists specifically binding IMP-2, and their use, in the prevention and treatment of diseases associated with expression of IMP-2. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding IMP-2 for the treatment of diseases associated with the expression of IMP-2. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding IMP-2.

Abstract: The invention encompasses a novel tumor marker TC1 which is present on tumor cells and absent on corresponding normal cells, nucleic acid encoding the tumor marker, and monoclonal antibodies to tumor marker TC1.

Abstract: The present disclosure concerns the treatment of a patient with autoimmune disease, including AIDS, by neutralizing, removing or inhibiting different types of interferons, tumor necrosis factor, HLA class II antigens, IgE, and other pathological factors and/or their receptors, as well as neutralizing, removing or inhibiting autoantibodies, including antibodies to target cells, CD4 cells and DNA. Treatment comprises administration of an autoimmune inhibitor, or extracorporeal exposure of the patient's fluid to an immunosorbent comprising an autoimmune inhibitor, followed by return of the treated fluid to the patient, or it comprises a combined therapy involving extracorporeal immunosorption in conjunction with the administration of an autoimmune inhibitor.

Abstract: An analytical device is provided. The device comprises a liquid-impervious top support layer that defines a rim around an open port. A porous reaction membrane having an upper surface and a lower surface is proximal to the top support layer, such that a portion of the reaction membrane upper surface and rim define a sample receiving well. The reaction membrane upper surface is sealed to the lower surface of the top support layer by water-insoluble adhesive so as to form a liquid-impervious seal therebetween. An absorbent body is proximal to and in liquid communication with the lower surface of the reaction membrane. The analytical device may further comprise a liquid-impervious bottom support layer which is attached to the lower surface of the absorbent body. The device can be used in immunoassays for the detection of a bindable substance in a liquid sample containing the target substance.

Abstract: An anti-ribonucleotide reductase (RNR) R2 subunit monoclonal antibody KM1054, KM1056 or KM1060, which belongs to the IgG2a subclass, reacts with R2 subunit of RNR, and inhibits RNR activity, is disclosed. It is effective for immunologically detecting RNR and for immunologically detecting the presence of human cancer cells.

Abstract: A method and bioreactor apparatus is described for growing plant cells, particularly to produce plant derived chemicals is described. Bioparticles (11) containing magnetically susceptible particles are provided in a column (12) surrounded by a solenoids (13, 14, 14A) which act to hold the bioparticles in position in the column. One of the solenoids with a magnetically susceptible screen (24) acts as a valve to allow a portion of the bioparticles to be removed from the column. The method is particularly described for producing daidzein and genistein.

Abstract: Disclosed is a heterodimeric T lymphocyte receptor subunit. The subunit consists of a signal peptide, variable, joining, constant, transmembrane, and cytoplasmic regions.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor subunit were determined using cDNA clones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressed and rearranged specifically in T cells and have significant sequence homologies to immunoglobulin V and C genes.T cell receptor subunits may be produced from the cDNA clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.

Abstract: Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e.g., by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.

Abstract: Antibodies, including monoclonal antibodies, specific for proliferating/angiogenic human endothelial cells such as human umbilical vein endothelial cells and human umbilical artery endothelial cells, and conjugates of these antibodies with a toxin material or label, are useful for inhibition of angiogenesis or for treatment of angiogenesis-dependent disease.

Abstract: The present invention provides novel human tumor proteins (collectively called TUPRO) and polynucleotides which identify and encode TUPRO. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding TUPRO. The invention also provides pharmaceutical compositions containing TUPRO or antagonists to TUPRO, and in the use of these compositions for the treatment of diseases associated with the expression of TUPRO. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding TUPRO for the treatment of diseases associated with the expression of TUPRO. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding TUPRO or anti-TUPRO antibodies which specifically bind to TUPRO.

Abstract: A method of determining the prognosis of a solid tumor is provided, in which a sample from a patient bearing a tumor is assayed for the presence of a protein which is immunologically cross-reactive with the hpr gene product, but not with haptoglobin 1 or haptoglobin 2. Also provided is a method for preparing antibodies specific for this diagnostic marker which correlates with early relapse and metastasis of breast and other cancers. The marker can be detected using immunological methods employing antibodies specific for Hpr protein and not cross-reactive with haptoglobins 1 or 2.

Abstract: A screening test for identifying individuals having a predisposition to develop ovarian cancer. The test involves measuring the phenotypic expression of the CA125 antigen in overtly normal ovarian surface epithelium (OSE) cells propagated in vitro. The OSE cells are preferably passaged repeatedly prior to measuring for the expression of the CA125 antigen. The test is based on the finding that OSE cells obtained from individuals having a family history of ovarian and/or breast cancer retain sub-populations of CA125 expressing cells for longer time periods in vitro than OSE cells derived from individuals not having a such a family history. The test provides an alternative means of identifying and monitoring women at risk of developing ovarian cancer, including women with hereditary ovarian cancer syndromes and women likely to develop sporadic (non-familial) ovarian cancer.

Abstract: A sensitive method for measurement of telomeric DNA content in human tissue, based upon the ratio of telomeric to centromeric DNA present in the tissue.

Abstract: This invention provides antibodies that bind to epitopes of human platelet-derived growth factor receptor (hPDGF-R) fragments, wherein the fragments comprise one or more platelet-derived growth factor (PDGF) ligand binding regions from extracellular domains D1, D2, and D3. Also provided are antibodies specific for domain D3, such as monoclonal antibodies directed to the intra-cysteine portion of domain D3.

Abstract: A new substrate of epidermal growth factor receptor and certain other tyrosine kinase receptors denominated eps15, polynucleotides encoding eps15, antisense eps15 polynucleotide, triple helix eps15 polynucleotide, antibodies to eps15, and assays for determining eps15.

Abstract: Disclosed is a process which achieves effective separation of components from red blood cells by aggregating cell membranes with an addition of a pH lowering agent, whereupon the solution is made subject to a separation step where a water soluble fraction is separated from cell membranes, and whereupon the cell membranes are extracted, and where lipids may be selectively separated and recovered by lowering the temperature of the extract.

Abstract: This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides.

Abstract: The present invention provides two human p24 vesicle trafficking proteins (designated individually as Hp24-1 and Hp24-2 and collectively as Hp24) and polynucleotides which identify and encode Hp24. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding Hp24 and a method for producing Hp24. The invention also provides for agonists, antibodies, or antagonists specifically binding Hp24, and their use, in the prevention and treatment of diseases associated with expression of Hp24. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding Hp24 for the treatment of diseases associated with the expression of Hp24. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding Hp24.

Abstract: Compounds and compositions for eliciting or enhancing immune reactivity to HER-2/neu protein are disclosed. The compounds include polypeptides and nucleic acid molecules encoding such peptides. The compounds may be used for the prevention or treatment of malignancies in which the HER-2/neu oncogene is associated.

Abstract: A method for producing a human lymphocyte producing an antibody specific to a desired antigen, a method for producing a monoclonal antibody, as well as monoclonal antibodies produced by the method, are described. The present invention provides a method for producing a human lymphocyte producing an antibody comprising, in the order mentioned, the steps of: transplanting human lymphocytes into an immunodeficient animal so that the human lymphocytes take in the animal body; immunizing the animal with a desired antigen so as to generate human lymphocytes producing an antibody specific to the antigen; and recovering the human lymphocytes producing the antibody from the animal.